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Abstract
Background: The FABP2 gene encodes for the intestinal FABP (IFABP) protein, which is expressed only
in intestinal enterocytes. A polymorphism at codon 54 in exon 2 of the FABP2 gene exchanges an Alanine
(Ala), in the small helical region of the protein, for Threonine (Thr). Given the potential physiological role
of the Ala54Thr FABP2 polymorphism, we assess in this study the local population frequency and analyze
possible associations with five selected markers, i.e. glycemia, total cholesterol, body mass index (BMI),
hypertension, and high Cardiovascular Risk Index (CVR index).
Methods: We studied 86 men and 116 women. DNA was extracted from a blood drop for genotype
analysis. Allele frequencies were calculated by direct counting. Hardy Weinberg Equilibrium was evaluated
using a Chi-square goodness of fit test.
For the polymorphism association analysis, five markers were selected, i.e. blood pressure, Framingham
Risk Index, total cholesterol, BMI, and glycemia.
For each marker, the Odds Ratio (OR) was calculated by an online statistic tool.
Results: Our results reveal a similar population polymorphism frequency as in previous European studies,
with q = 0.277 (95% confidence limits 0.234–0.323). No significant association was found with any of the
tested markers in the context of our Argentine nutritional and cultural habits. We did, however, observe
a tendency for increased Cholesterol and high BMI in Thr54 carriers.
Conclusion: This is the first study to look at the population frequency of the Thr54 allele in Argentina.
The obtained result does not differ from previously reported frequencies in European populations.
Moreover, we found no association between the Thr54 allele and any of the five selected markers. The
observed tendency to increased total cholesterol and elevated BMI in Thr54 carriers, even though not
significant for p < 0.1 could be worth of further investigation to establish whether the Thr54 variant should
be taken into consideration in cardiovascular prevention strategies.
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Background
Fatty acid-binding proteins (FABPs) are small intracellular
polypeptides found in many tissues, involved in fatty acid
transfer and metabolism [1] and encoded by a family of
different genes. The FABP2 gene encodes intestinal FABP
protein (IFABP), and is only expressed in the absorptive
simple columnar epithelial cells of the intestine (entero-
cytes) [2]. Several functions of IFABP protein have been
proposed, these include the facilitation of cellular uptake
and/or transport of long-chain fatty acids within entero-
cytes [3]. The IFABP protein contains two beta-sheet struc-
tures surround a cavity into which the ligand binds [4].
The major conformational adjustment between the struc-
ture of free IFABP and IFABP bound to fatty acid, occurs at
a tight turn containing residues 54 and 55. These residues
shift position when long-chain fatty acids are bound to
the protein. Therefore, even a subtle change in the amino
acid sequence of this turn could affect the structural prop-
erties of IFABP in such a way as to alter its ligand affinity
[5].
A polymorphism at codon 54 in exon 2 of the human
FABP2 gene exchanges an Alanine (Ala) in the small heli-
cal region of the protein for Threonine (Thr). Different
studies suggest that the Ala-to-Thr substitution is in fact a
functional mutation [6,7]. It is reasonable to speculate
that if the FABP2 gene polymorphism in any way modifies
the absorption of fatty acids, it could in turn affect the
lipid metabolism and/or correlate with cardiovascular dis-
ease (CVD) risk. Earlier studies have shown that the IFABP
Thr54 allele is significantly associated with higher total
cholesterol, with stroke incidence [8], elevation of fasting
and postprandial triglyceride [9], insulin resistance [2,6],
and higher nonesterified fatty acid (NEFA) concentrations
[10]. There are many contradicting studies, however, that
have found non-significant association with these param-
eters [11-14]. In the light of the potential physiological
role of the FABP2 polymorphism, we assessed the local
population frequency of the Thr54 allele and analyzed its
possible associations with five selected markers, i.e. glyc-
emia, total cholesterol, body mass index (BMI), hyperten-
sion and cardiovascular risk index (CVR index). Our
results reveal a similar population polymorphism fre-
quency as in previous European studies and a not signifi-
cant association with none of the tested markers in the
context of our argentine nutritional and cultural habits.
Methods
Subjects
We recruited 202 volunteers (mean age 53 years) from
various Public Administration Offices, including 86 men
(aged between 35 and 75 years, mean age 51) and 116
women (aged between 45 and 75 years, mean age 56). The
means in the sample were: cholesterol level 198,34
(190,52 for men and 204,27 for women), diastolic blood
pressure: 79,38 (82,93 for men and 76,96 for women),
systolic blood pressure: 127,22 (131,15 for men and
124,26 for women) and BMI: 28,45 (28,86 for men and
28,13 for woman). In the 202 subjects, there were only 11
diabetics. On receiving written informed consent from all
participants included in this population screening study,
a drop of blood was collected for total cholesterol and gly-
cemia analysis using commercial kits (Accu-Chek Instant
Plus, Roche Diagnostic). A second drop of blood was col-
lected on a DNAase free paper (Nucleic Paper, Biodynam-
ics S.R.L, Buenos Aires, Argentina) for DNA extraction.
Systolic and diastolic blood pressure was measured by a
physician. BMI was calculated as weight (kg) divided by
height squared (m2). The ethical committee of the Public
Health Care Program for Government Employees (OSEP,
Obra Social del Empleado Publico) approved the study.
Cardiovascular risk assessment by calculation of the 
Framingham Risk Index
The cardiovascular risk was calculated for each individual
by the Framingham Index according to the National Cho-
lesterol Education Program (NCEP) Adult Treatment
Panel (ATP) III guidelines [15]. This index takes into
account the following variables: sex, age, blood pressure,
total cholesterol, HDL and smoking status. The HDL
measure was excluded from this study because of its low
impact on the total score for the risk calculation. The total
score was obtained by summing the partial scores for each
of the variables mentioned. The total score of 10 was
established as the threshold, with a 0 to 9 total score
implying low risk status and a 10 or higher total score
implying high risk status.
Genotype analysis
To extract DNA, a piece of 2 mm radio was cut out from
the blood drop on DNAse free paper, added to 100 μl ster-
ile water, and then incubated for 30 minutes at 95°C. For
PCR reaction 10 μl were used. Some DNA samples which
did not amplify well were diluted 1:10 or 1:20.
DNA was amplified in a total volume of 20 μl, with the
upstream primer: 5'ACAGGTGTTAATATAGTGAAAAG3'
and the downstream primer: 5'
TACCCTGAGTTCAGTTCCGTC3' [6]. The PCR program
consisted of an initial and final hold of 94°C and 72°C
for 3 minutes, and 30 cycles of 94°C, 55°C, and 72°C,
with each step of 30 seconds duration.
For Restriction Fragment length Polymorphism (RFLP)
analysis, 5 μl of PCR product were incubated with 0.4 μl
of enzyme CfoI (GCG/C) (10 U/μl, Promega) in a final
volume of 10 μl for 1 hour at 37°C.BMC Medical Genetics 2007, 8:39 http://www.biomedcentral.com/1471-2350/8/39
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The products were run on a 10% non-denaturing PAGE
for 50 minutes at 110 V. Bands were observed after Ethid-
ium bromide staining and UV light exposure.
Allele frequency and polymorphism association analysis
Allele frequencies were calculated by direct counting.
Hardy Weinberg Equilibrium was evaluated using a Chi-
square goodness of fit test.
For the polymorphism association analysis, five markers
were selected, i.e. blood pressure, Framingham Risk
Index, total cholesterol, BMI, and glycemia. Each parame-
ter was assigned a threshold value, established by the RCP
Program, as follows:
1-Hypertension >140 mmHg systolic or >90 mmHg
diastolic; 2-Framingham Risk Index >9 total score; 3-BMI
>24 kg/m2; 4-Total cholesterol > 240 mg/dl; 5-Glycemia
>110 mg/dl after 8 h fasting or >140 mg/dl postprandial.
For each marker, the Odds Ratio (OR) was calculated by
the online statistic tool [16].
Results
The Thr54 allele frequency in Argentina
To assess the polymorphism frequency in our region,
DNA samples of 202 individuals (86 men and 116
women) were analyzed for the Ala/Thr polymorphism.
The included subjects belonged to an ongoing Regional
Cardiovascular Prevention Program (RCP program),
organised by the Public Health Care Program for Govern-
ment Employees (OSEP) of Mendoza (Argentina). This
programme focuses on the assessment of an individual
cardiovascular risk index in order to apply prevention
strategies in the analyzed population.
The observed population genotype composition was: 105
Ala/Ala homozygous, 82 Ala/Thr heterozygous and 15
Thr/Thr homozygous (Table 1).
Eventhough the province of Mendoza has a total popula-
tion of almost 1.600.000 individuals, it presents a non-
homogenous population distribution provoked by the
migration of families to the surroundings of the capital
city of Mendoza. We therefore decided to carefully analyze
our genotype composition results in order to detect
whether our sample could be affected by endogamic
behaviour. The cluster of inhabitants around the city
could lead to inbreeding and consequently reduce the
number of observed homozygous, and affect the allele fre-
quency. In order to assess whether this was interfering
with our population sample, the amount of observed het-
erozygous and homozygous for the Ala54Thr polymor-
phism was used in the formula F = He-Ho/He (where He
and Ho are expected and observed heterozygous). How-
ever, a negative (-) 0,02 inbreeding rate was found, con-
firming there is no endogamic behaviour in our
population that could have affected the allele frequency.
The calculated Thr54 allele frequency was q = 0.277 (95%
confidence limits 0.234–0.323). In a subsequent analysis
of the equilibrium of the populations genotypes, the
results revealed that the proportion of hetero and
homozygous did not differ significantly from the expected
genotypes for a population in Hardy Weinberg equilib-
rium (Table 1) (p > 0.05, Chi squared goodness of fit),
which is consistent with our first finding of non-endo-
gamic behaviour.
The assessment of the polymorphism frequency in Argen-
tina with similar values as in European countries [17]
encouraged us to subsequently analyze possible geno-
type-phenotype associations.
Polymorphism association analysis reveals no significant 
impact on CVD risk markers
For the genotype-phenotype association assessment, the
phenotypic information of the 202 individuals included
in the study was used. Association analysis with allele
Thr54 was performed on five selected parameters, i.e. gly-
cemia, total cholesterol, BMI, hypertension, and cardio-
vascular risk (calculated by the Framingham Risk Index).
Comparisons were performed between subjects that car-
ried at least one Thr54 allele (homozygous Thr/Thr and
heterozygous Ala5Thr) and non-carriers of the allele
Thr54 (homozygous Ala/Ala). For each parameter, a
threshold value was established by the RCP Program (see
Methods).
Our study reveals no significant association (p > 0.05)
between the Thr54 allele and any of the analyzed param-
eters (Table 2). The ORs represent the magnitude of asso-
ciation between the genotype and disease, consequently
ORs with a 95%CI including the value 1 are indicative of
no difference between Thr54 carriers and non-carriers for
that factor. We analysed the five markers in male Thr54
carriers respect to female Thr54 carriers. We did not find
any significant difference (for p = 0,05) between gender
for BMI, cholesterol, blood pressure, and glycemia.
These results are in accordance with other previous publi-
cations that found no major contribution of allele Thr54
on these phenotypic parameters [11-14].
Despite the non-significant association results, we con-
sider it worth noting that the ORs for Cholesterol (2.01),
BMI (1.44) and CVD risk (1.25) are >1. When we ana-
lyzed the distribution of Thr54 carriers and non-carriers
combining two of these three parameters, we observed an
increased number of polymorphism carriers with highBMC Medical Genetics 2007, 8:39 http://www.biomedcentral.com/1471-2350/8/39
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cholesterol and high BMI (Figure 1). Notice in Figure 1a
that the quadrant corresponding to high cholesterol and
high BMI shows more carrier individuals (17/97) than
non-carriers (10/105). This not significant difference for p
< 0.1 but subtle tendency was not observed in the rest of
the parameter combinations that were analyzed (data not
shown). These results reveal that even though the markers
for Cholesterol and BMI do not show a significant associ-
ation with the polymorphism when they are analyzed on
their own, a subtle tendency is observed when they are
analyzed in combination.
Discussion
There are no previous reports about the prevalence of the
Thr54 FABP2 variant in our region. In the sample tested,
the observed Thr54 frequency (q = 0,277) is similar to that
reported in eleven different European countries (0.276)
[17], suggesting that the colonising European popula-
tions, mainly from Italy and Spain, introduced the same
original allele frequency in this continent and that this fre-
quency has remained conserved. The fact that the propor-
tion of carriers has not changed and that the
polymorphism is in a Hardy Weinberg equilibrium sug-
gests that there is no significant natural selection pressure
acting against individuals with the Thr54 FABP2 variant
living in Mendoza, Argentina. Other South American fre-
quency analysis of Thr54 were reported by a Chilean
group, who found a q = 0.4 in 63 obese and not obese
women [18], and a Brazilian study that reported a q = 0.25
in 1042 diabetes type 2 individuals [19]. Even though
both analyses are performed on specific study sample, i.e.
obese and diabetic individuals, the Brazilian frequency in
1042 individuals is similar to that observed by our group
in Argentina.
It is well known that the single nucleotide polymorphism
(SNP) at codon 54 is a missence variant that has a definite
effect on the primary structure of the protein and affects its
fatty acid binding properties. It is not known, however,
whether this change can affect the lipid metabolism of car-
riers [20]. Many earlier studies have reported associations
between this polymorphism and insulin resistance, BMI,
dyslipidemia, stroke, metabolic syndromes and hypertrig-
lyceridemia [2,6,8-10,21-23]. In contrast, other studies
report no association with the same parameters [11-14].
Part of the discrepancy among the studies may come from
the different dietary habits of the analyzed populations.
For example, the lack of association found in a Finnish
population [24] could be related to its prevailing fish diet
where the Thr54 variant may not cause any phenotypical
manifestation. Therefore, it was important to assess some
of these associations in Argentina, characterized by the
consumption of significant amounts of beef (i.e. 68 kg of
beef/year/habitant). This diet is rich in proteins and fats
and poor in fibres and fish [25]. In addition, it was rele-
vant for the local RCP Program to develop health preven-
Table 2: Association analysis of the Thr54 polymorphism and phenotypic parameters
Phenotypic parameters and threshold values OR CI (p = 0.05) Significance
Cholesterol > 240 mg/ml 2.01 0.87–4.65 NS
BMI>24 kg/m2 1.44 0.7–2.98 NS
Cardiovascular risk >9 1.25 0.62–2.5 NS
Diastolic blood pressure > 90 mmHg 0.93 0.51–1.69 NS
Systolic blood pressure > 140 mmHg 0.86 0.44–1.47 NS
Glycemia > 140 mg/dl postprandial 0.76 0.33–1.76 NS
ORs were calculated as ratio between polymorphism carriers and non-carriers with high blood pressure (>140 mmHg systolic or 90 mmHg 
diastolic), high Framingham Risk Index (>9) high cholesterol (> 240 mg/dl), high BMI (>24 kg/m2), and high glycemia (>110 mg/dl after 8 h fasting or 
>140 postprandial mg/dl). 95% Confidence Intervals for p = 0.05 are shown. All CI include OR = 1, indicating no significant association between the 
polymorphism and the parameters tested.
Table 1: Genotype analysis in the study subjects
Homozygous Ala54/Ala54 Homozygous Ala54/Thr54 Homozygous Thr54/Thr54
Observed number 105 82 15
Expected number 105.5 81 15.5
X2n.s. p > 0.05 q(Thr54)= 0.2777 (95% CI: 0.234–0.323) Sample size: 202
In a sample of 202 individuals, genotype analysis was performed for the polymorphism Ala/Thr. The observed number of homozygous and 
heterozygous was not significantly different from that expected in a population in Hardy Weinberg Equilibrium. The Thr54 frequency found in the 
Argentine populations was q = 0.277.BMC Medical Genetics 2007, 8:39 http://www.biomedcentral.com/1471-2350/8/39
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Association of Thr54 carriers with the combination of markers: i.e. cholesterol, BMI and cardiovascular risk index Figure 1
Association of Thr54 carriers with the combination of markers: i.e. cholesterol, BMI and cardiovascular risk 
index. Sample distribution for Thr54 carriers (homozygous Thr/Thr and heterozygous Ala/Thr) and non-carriers (homozygous 
Ala/Ala) regarding two features: (a) BMI and Choslesterol (b) Cardiovascular risk index (CV Risk) and Cholesterol. (c) Cardio-
vascular risk index (CV Risk) and BMI. The crossing lines show the threshold values for BMI (24 kg/m2), cholesterol (220 mg/
dl), and high risk (9 total score)
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tion strategies based on educational programs of life style
and nutritional habits.
Our results indicate that in the assessed population, the
allele Thr54 does not influence the glycemia levels nor the
blood pressure (odds ratio approaching 1).
The Cholesterol levels, BMI and CVR index are not signif-
icantly influenced by the Thr54, but show ORs >1. These
tendencies for increased risk are better manifested when
BMI and Cholesterol are analysed in a combination. This
observation does, however, not prove association or cau-
sality. The sample size was small, and these observed ten-
dencies require further investigation in order to reveal
whether the influences become significant and whether it
could be related to the meat and fat-rich diet prevailing in
Argentina.
Conclusion
We present the first study investigating the Thr54 allele
frequency in Argentina and its association with five cardi-
ovascular risk markers. The population frequency of the
Thr54 allele in Argentina does not differ from previously
reported frequencies in European populations. Moreover,
we found no association between the Thr54 allele and any
of the five selected markers. Although the observed ten-
dency for increased total cholesterol and elevated BMI in
Thr54 carriers was not significant, this will require further
investigation to establish whether the Thr54 variant
should be taken into consideration in cardiovascular pre-
vention strategies in our country.
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